The ADAGIO study demonstrated a symptomatic benefit for rasagiline in early Parkinson's
disease (PD) and suggested a disease‐modifying effect. Evidence indicates that
mitochondrial dysfunction plays a role in the pathogenesis of PD and that this may be the
site of effect for rasagiline. In this systematic review, evidence for the role of mitochondria in
the pathogenesis of PD are reviewed in light of other proposed mechanisms of neuronal
degeneration and the actions of rasagiline and its component parts, namely propargylamine …